EE05174B1 - Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud hulgiskleroosi ja teiste meliinikaotusega seotud haiguste raviks - Google Patents

Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud hulgiskleroosi ja teiste meliinikaotusega seotud haiguste raviks

Info

Publication number
EE05174B1
EE05174B1 EEP200300139A EEP200300139A EE05174B1 EE 05174 B1 EE05174 B1 EE 05174B1 EE P200300139 A EEP200300139 A EE P200300139A EE P200300139 A EEP200300139 A EE P200300139A EE 05174 B1 EE05174 B1 EE 05174B1
Authority
EE
Estonia
Prior art keywords
preparation
treatment
pharmaceutical composition
multiple sclerosis
loss diseases
Prior art date
Application number
EEP200300139A
Other languages
English (en)
Inventor
Proudfoot Amanda
N. C. Wells Timothy
Kosco-Vilbois Marie
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200300139A publication Critical patent/EE200300139A/et
Publication of EE05174B1 publication Critical patent/EE05174B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200300139A 2000-10-04 2001-10-03 Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud hulgiskleroosi ja teiste meliinikaotusega seotud haiguste raviks EE05174B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00121665 2000-10-04
PCT/EP2001/011428 WO2002028419A2 (en) 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
EE200300139A EE200300139A (et) 2003-06-16
EE05174B1 true EE05174B1 (et) 2009-06-15

Family

ID=8170011

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300139A EE05174B1 (et) 2000-10-04 2001-10-03 Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud hulgiskleroosi ja teiste meliinikaotusega seotud haiguste raviks

Country Status (31)

Country Link
US (1) US7402303B2 (et)
EP (1) EP1326628B1 (et)
JP (1) JP3908165B2 (et)
KR (1) KR100837898B1 (et)
CN (1) CN1285381C (et)
AR (1) AR030854A1 (et)
AT (1) ATE265222T1 (et)
AU (2) AU2002215919B2 (et)
BG (1) BG66137B1 (et)
BR (1) BR0114407A (et)
CA (1) CA2423616C (et)
CZ (1) CZ303409B6 (et)
DE (1) DE60103078T2 (et)
DK (1) DK1326628T3 (et)
EA (1) EA006137B1 (et)
EE (1) EE05174B1 (et)
ES (1) ES2217199T3 (et)
HK (1) HK1062811A1 (et)
HR (1) HRP20030215B1 (et)
HU (1) HUP0302194A3 (et)
IL (2) IL155178A0 (et)
MX (1) MXPA03003008A (et)
NO (1) NO330278B1 (et)
PL (1) PL204231B1 (et)
PT (1) PT1326628E (et)
RS (1) RS50738B (et)
SI (1) SI1326628T1 (et)
SK (1) SK287523B6 (et)
UA (1) UA77950C2 (et)
WO (1) WO2002028419A2 (et)
ZA (1) ZA200302315B (et)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553483B2 (en) 2001-12-17 2009-06-30 Merck Serono Sa Chemokine mutants acting as chemokine antagonists
DE60303929T2 (de) 2002-04-04 2006-08-10 Applied Research Systems Ars Holding N.V. Chemokin-muntanten mit verbesserter oraler bioverfügbarkeit
EP1575608B1 (en) 2002-12-23 2008-05-07 Laboratoires Serono SA Use of cc-chemokine ccl5/rantes mutants against liver diseases
CA2534828A1 (en) * 2003-10-22 2005-05-06 Applied Research Systems Ars Holding N.V. Novel cxcl8 antagonists
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
DE60304435T2 (de) * 2004-01-19 2006-08-24 Ares Trading S.A. Verfahren zur Reinigung von in Bakterien exprimierten Proteinen
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
EP1760110B1 (en) * 2005-09-03 2011-11-02 Samsung SDI Co., Ltd. Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane
GB0614755D0 (en) 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
MX2010001307A (es) 2007-08-02 2010-07-30 Novimmune Sa Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
CN102781952B (zh) * 2010-02-08 2015-09-02 宾夕法尼亚大学托管会 编码rantes的核酸分子、包含其的组合物以及其使用方法
CN112469430A (zh) 2018-05-28 2021-03-09 日内瓦大学 抑制大脑炎症的方法
WO2022093857A1 (en) * 2020-10-26 2022-05-05 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1998006751A1 (en) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
DE69832216T2 (de) 1997-12-23 2006-05-24 Fondazione Centro San Raffaele Del Monte Tabor RANTES-Mutanten und therapeutische Anwendungen davon
JP2002535376A (ja) 1999-01-29 2002-10-22 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Ｃｃｒ１アンタゴニストを用いた脱髄性炎症性疾患の治療方法

Also Published As

Publication number Publication date
WO2002028419A2 (en) 2002-04-11
CA2423616C (en) 2010-03-16
ATE265222T1 (de) 2004-05-15
US7402303B2 (en) 2008-07-22
PL362350A1 (en) 2004-10-18
SK4062003A3 (en) 2003-08-05
MXPA03003008A (es) 2003-07-14
HRP20030215A2 (en) 2005-02-28
CN1477969A (zh) 2004-02-25
BG66137B1 (bg) 2011-07-29
HUP0302194A2 (hu) 2003-10-28
PT1326628E (pt) 2004-09-30
DK1326628T3 (da) 2004-08-09
IL155178A0 (en) 2003-11-23
WO2002028419A3 (en) 2002-06-13
DE60103078T2 (de) 2005-04-07
EA200300439A1 (ru) 2003-08-28
EE200300139A (et) 2003-06-16
CN1285381C (zh) 2006-11-22
SI1326628T1 (en) 2004-10-31
NO20031525D0 (no) 2003-04-03
AU1591902A (en) 2002-04-15
HUP0302194A3 (en) 2005-12-28
JP2004510426A (ja) 2004-04-08
CZ2003947A3 (cs) 2003-11-12
YU25703A (sh) 2006-05-25
ES2217199T3 (es) 2004-11-01
EP1326628B1 (en) 2004-04-28
HRP20030215B1 (en) 2011-09-30
EP1326628A2 (en) 2003-07-16
AR030854A1 (es) 2003-09-03
CZ303409B6 (cs) 2012-09-05
PL204231B1 (pl) 2009-12-31
HK1062811A1 (en) 2004-11-26
JP3908165B2 (ja) 2007-04-25
IL155178A (en) 2009-07-20
RS50738B (sr) 2010-08-31
UA77950C2 (en) 2007-02-15
ZA200302315B (en) 2004-03-25
CA2423616A1 (en) 2002-04-11
BG107685A (bg) 2003-11-28
EA006137B1 (ru) 2005-10-27
US20040101509A1 (en) 2004-05-27
BR0114407A (pt) 2003-07-29
KR100837898B1 (ko) 2008-06-13
KR20030034238A (ko) 2003-05-01
SK287523B6 (sk) 2011-01-04
AU2002215919B2 (en) 2005-11-24
NO20031525L (no) 2003-04-03
NO330278B1 (no) 2011-03-21
DE60103078D1 (de) 2004-06-03

Similar Documents

Publication Publication Date Title
HK1047231A1 (en) Oral pharmaceutical forms of administration with adelayed action with tramadol
NO20003218L (no) Oral farmasøytisk doseringsform med forlenget frigivningsvirkning
HK1076723A1 (en) Highly selective norepinephrine reuptake inhibitors and the use for the preparation of the medicament thereof
EE200200274A (et) Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
HUP0100101A3 (en) Prostaglandin agonists, pharmaceutical compositions comprising thereof and their use
EE04578B1 (et) Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nendesolvaatide suu kaudu manustamiseks
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
HUP0102281A3 (en) Prodrugs of dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
IL196301A0 (en) Medicament for the treatment of hapatitis c
NO975831D0 (no) Nytt farmasöytisk preparat med anestetisk virkning
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
MXPA02004770A (es) Composiciones terapeuticas y metodos para su uso.
HK1048986A1 (en) 2'-Substituted 1,1'-iphenyl-2-carbonamides, methodfor the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds.
EE05174B1 (et) Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud hulgiskleroosi ja teiste meliinikaotusega seotud haiguste raviks
EE200200620A (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette nähtud ateroskleroosi ravimiseks ja/või ennetamiseks
HUP0301333A3 (en) Pharmaceutical superdisintegrant, process for its preparation and its use
FI956298A0 (fi) 3-fenyyli-isokinolin-1(2H)-oneja, niiden valmistus ja terapeuttinen käyttö
EE200300363A (et) N-(püridinüül)-1H-indool-1-amiinühendite kasutamine ravimi valmistamiseks, mis on ette nähtud müeliinikaotusega seotud haiguste ja seisundite ravimiseks
HRP20020893A2 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
NO20002526D0 (no) Mellomprodukt med høyt legemiddelinnhold og orale doseringspreparater med modifisert frigivelse samt fremgangsmÕter for fremstilling derav
EE03510B1 (et) Tsisapriidi pikendatud vabastamisega ravimvorm suukaudseks manustamiseks, selle valmistamine ja kasutamine
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
EE200200551A (et) Oligosahhariide sisaldav farmatseutiline kompositsioon, oligosahhariidid, nende valmistamine ja raviotstarbeline kasutamine
EE200200480A (et) Memnopeptiidühend, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20131003